Videos

How I Practice Now: Treating FL During the Global Pandemic

04/23/2020

John Allan, MD, Weill Cornell Medicine, New York, NY, explains the impact the COVID-19 pandemic has had on his practice, particularly the treatment of patients with follicular lymphoma and other indolent lymphomas.

Recent News

News

Trastuzumab Deruxtecan Plus Paclitaxel, Trastuzumab, and Pertuzumab Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer

05/11/2026

Stephanie Holland

Post hoc analysis results from the phase 3 DESTINY-Breast11 trial demonstrated that neoadjuvant trastuzumab deruxtecan plus paclitaxel, trastuzumab, and pertuzumab improved residual cancer burden and pathologic response in HER2-positive early...

Post hoc analysis results from...

05/11/2026

Oncology

News

Sacituzumab Govitecan Plus Trastuzumab Showed Limited Activity After T-DXd in HER2-Positive Metastatic Breast Cancer

05/11/2026

Stephanie Holland

According to results from the phase 2 SATEEN trial, sacituzumab govitecan plus trastuzumab demonstrated limited clinical activity in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan.

According to results from the...

05/11/2026

Oncology

FDA Approval

FDA Approves Zenocutuzumab for Patients With NRG1 Fusion-Positive Advanced Cholangiocarcinoma

05/08/2026

Stephanie Holland

Based on results from the phase 2 eNRGy trial, the FDA has approved zenocutuzumab for previously treated patients with advanced cholangiocarcinoma harboring NRG1 gene fusions.

Based on results from the phase...

05/08/2026

Oncology

News

Daraxonrasib Shows Clinical Promise in Patients With RAS-mutated Pancreatic Ductal Adenocarcinoma

05/07/2026

Stephanie Holland

Results from a phase 1/2 study demonstrated that the daraxonrasib showed clinical promise in previously treated patients with RAS-mutated pancreatic ductal adenocarcinoma.

Results from a phase 1/2 study...

05/07/2026

Oncology

FDA Approval

FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications

05/07/2026

Stephanie Holland

Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.

Based on pharmacokinetic...

05/07/2026

Oncology

FDA Alerts

Camizestrant Fails to Gain Support from the FDA’s Advisory Committee in ESR1-Mutated Advanced Breast Cancer

05/07/2026

Stephanie Holland

Based on results from the SERENA-6 trial, the FDA’s Oncologic Drugs Advisory Committee has voted that camizestrant plus CDK4/6 inhibition does not demonstrate a favorable benefit-risk profile in patients with HR-positive, HER2-negative...

Based on results from the...

05/07/2026

Oncology

News

Complete Consolidative Radiotherapy Improves Survival in Extensive-Stage Small Cell Lung Cancer

05/07/2026

Emily Estrada

Results from a retrospective cohort study demonstrated that completion of consolidative radiotherapy was associated with significantly improved survival outcomes in patients with extensive-stage small cell lung cancer.

Results from a retrospective...

05/07/2026

Oncology

News

Oligoprogression Predicts Improved Survival After Chemoimmunotherapy in Relapsed Small Cell Lung Cancer

05/07/2026

Emily Estrada

Results from a retrospective analysis demonstrated that patterns of post-chemoimmunotherapy progression were strongly associated with outcomes in relapsed small cell lung cancer.

Results from a retrospective...

05/07/2026

Oncology

News

Giredestrant Demonstrates Antiproliferative Activity in Premenopausal Patients With Early Breast Cancer

05/07/2026

Stephanie Holland

Results from the phase 2 PREcoopERA trial demonstrated that giredestrant shows antiproliferative activity in premenopausal ER-positive, HER2-negative early breast cancer.

Results from the phase 2...

05/07/2026

Oncology

News

Glecirasib-Based Regimens Show Promise in KRAS G12C-Mutant Metastatic Colorectal Cancer

05/07/2026

Emily Estrada

Combined results from the JAB-21822-1002 and JAB-21822-1007 trials demonstrate that glecirasib shows clinical promise both alone and in combination with cetuximab in KRAS G12C-mutated locally advanced or metastatic colorectal cancer.

Combined results from the...

05/07/2026

Oncology